Skip to main content
Log in

The COPD pipeline

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1: The COPD pipeline.

References

  1. Kardos, P. et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175, 144–149 (2007).

    Article  CAS  Google Scholar 

  2. Maltais, F. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients (Abstract 5557). Eur. Respir. J. 36 (Suppl. 54), 1014s (2010).

    Google Scholar 

  3. Franciosi, L. G. et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from our four clinical trials. Lancet Respir. Med. 9, 714–727 (2013).

    Article  Google Scholar 

  4. GBI Research. Chronic Obstructive Pulmonary Disease (COPD) Market to 2019. GBIHC299MR (2013).

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yasser Mushtaq.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mushtaq, Y. The COPD pipeline. Nat Rev Drug Discov 13, 253–254 (2014). https://doi.org/10.1038/nrd4254

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4254

  • Springer Nature Limited

Navigation